Enliven Therapeutics, Inc. (Nasdaq: ELVN) announces it has priced an upsized public offering of common stock and pre-funded warrants. According to the company’s release and accompanying coverage, the offering is larger than initially planned and is priced as a combination of shares and pre-funded warrants. The company describes the transaction as a public offering and provides the pricing details for both securities. Enliven is a clinical-stage biopharmaceutical company focused on small molecule therapeutics. The outlets report that the offering is conducted through a standard public-market process and that the pre-funded warrants are included alongside the common stock to provide investors an additional option in the capital raise. The filings and coverage indicate the offering size is $400 million, reflecting the upsized terms. The announcement is dated June 11, 2026, and is issued from Burlingame, California. Terms such as the use of proceeds and closing timeline are typically addressed in the company’s offering documents; the provided excerpts focus primarily on the pricing and size of the offering.